Details of the Drug

General Information of Drug (ID: DM2F8XZ)

• Drug Name: Salicyclic acid
• Synonyms: Salicylic acid; salicylic acid; 2-Hydroxybenzoic acid; 69-72-7; o-hydroxybenzoic acid; 2-Carboxyphenol; o-Carboxyphenol; Salonil; Rutranex; Retarder W; Keralyt; Freezone; Duoplant; Saligel; Ionil; Psoriacid-S-stift; salicylate; Stri-Dex; Salicylic acid soap; Benzoic acid, 2-hydroxy-; Salicylic acid collodion; Verrugon; Phenol-2-carboxylic acid; Acidum salicylicum; Trans-Ver-Sal; Orthohydroxybenzoic acid; 2-Hydroxybenzenecarboxylic acid; Acido salicilico; Ionil-Plus; Salicylic acid, tech; Kyselina salicylova; Clear away wart remover; Duofil wart; Domerine; Duofilm; Occlusal; SAX; Salicylate; Sebucare; Sebulex; Acido salicilico [Italian]; Advanced pain relief callus removers; Advanced pain relief corn removers; Akurza Cream; Akurza Lotion; DHS Sal Shampoo; DuoPlant Gel; Duofil wart remover; Hydrisalic Gel; Ionil plus; Kyselina salicylova [Czech]; Mediplast pads; O Hydroxybenzoic Acid; Ortho Hydroxybenzoic Acid; Retarder SAX; Salex Cream; Salex Lotion; CMC_13852; K 537; ATA fraction 10, ammonium salt; Acid, Salicylic; Acido o-idrossibenzoico; Acido o-idrossibenzoico [Italian]; Kyselina 2-hydroxybenzoova; Kyselina 2-hydroxybenzoova [Czech]; O-Carboxyphenol; O-hydroxybenzoic acid; Ortho-Hydroxybenzoic Acid; P&S Shampoo; Phenol derivative, 7; Propa pH Peel-Off Acne Mask; SALICYLIC ACID (SEE ALSO ALPHA HYDROXY ACIDS); SALICYLIC ACID, ACS; Salicylic acid & Sulfur Soap; Salicylic acid (TN); Salicylic acid [USAN:JAN]; Acid, 2-Hydroxybenzoic; Acid, o-Hydroxybenzoic; Acid, ortho-Hydroxybenzoic; BENZOIC ACID,2-HYDROXY SALICYLIC ACID; Dr Scholl's callus removers; Dr Scholl's corn removers; Dr Scholl's wart remover kit; Salicylic acid (6CI,8CI); Salicylic acid (JP15/USP); Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid); Salicylic acid-ring-UL-14C; ALPHA/BETA HYDROXY ACIDS (SALICYLIC ACID) (SEE ALPHA/BETA HYDROXY ACIDS); Benzoic acid, 2-hydroxy-(9CI); E9A559BE-383B-4F83-BC02-3031D03D558A; 2 Hydroxybenzoic Acid; 2-hydroxy(1-14c)benzoic acid; SALICYLATE

Indication

Disease Entry	ICD 11	Status	REF
Seborrhoeic dermatitis	EA81	Approved	[1], [2], [3]

• Therapeutic Class: Antiinflammatory Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 138.12
  Topological Polar Surface Area (xlogp); 2.3
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [5]
  Elimination: About 10% of drug is excreted unchanged in the urine [6]
  Metabolism: The drug is not metabolised [6]
  Vd: The volume of distribution (Vd) of drug is 0.17 L/kg [6]
  Water Solubility: The ability of drug to dissolve in water is measured as 2.51 mg/mL [4]
• Chemical Identifiers:
  Formula: C7H6O3
  IUPAC Name: 2-hydroxybenzoic acid
  Canonical SMILES: C1=CC=C(C(=C1)C(=O)O)O
  InChI: InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)
  InChIKey: YGSDEFSMJLZEOE-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 338
  ChEBI ID: CHEBI:16914
  CAS Number: 69-72-7
  DrugBank ID: DB00936
  TTD ID: D07HBX
  VARIDT ID: DR00556
  INTEDE ID: DR1458

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[7]
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[8]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[8]
Carbonic anhydrase IV (CA-IV)	TTZHA0O	CAH4_HUMAN	Inhibitor	[8]
Carbonic anhydrase VI (CA-VI)	TTCFSPE	CAH6_HUMAN	Inhibitor	[8]
Carbonic anhydrase XII (CA-XII)	TTSYM0R	CAH12_HUMAN	Inhibitor	[8]
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[9]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium-coupled monocarboxylate transporter 2 (SLC5A12)	DTM301H	SC5AC_HUMAN	Substrate	[10]
Probable small intestine urate exporter (SLC17A4)	DTHE530	S17A4_HUMAN	Substrate	[11]
Monocarboxylate transporter 2 (SLC16A7)	DTLT3UG	MOT2_HUMAN	Substrate	[12]
Monocarboxylate transporter 1 (SLC16A1)	DT342ZG	MOT1_HUMAN	Substrate	[13]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9) Main DME	DE5IED8	CP2C9_HUMAN	Substrate	[14]

Molecular Expression Atlas of This Drug

• The Studied Disease: Seborrhoeic dermatitis
• ICD Disease Classification: EA81

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 1 (COX-1)	DTT	PTGS1	3.97E-03	0.16	0.43
Sodium-coupled monocarboxylate transporter 2 (SLC5A12)	DTP	SMCT2	3.54E-01	5.45E-03	5.29E-02
Monocarboxylate transporter 2 (SLC16A7)	DTP	MCT2	9.19E-03	-3.31E-01	-5.56E-01
Probable small intestine urate exporter (SLC17A4)	DTP	SLC17A4	8.94E-01	-9.82E-03	-6.82E-02
Monocarboxylate transporter 1 (SLC16A1)	DTP	MCT1	2.27E-02	4.13E-01	6.05E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Salicyclic acid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Salicyclic acid caused by Sodium bicarbonate mediated altered urine pH.	Acidosis [5C73]	[66]
Tromethamine	DMOBLGK	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Salicyclic acid caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[66]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Glibenclamide.	Acute diabete complication [5A2Y]	[67]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Insulin-glulisine.	Acute diabete complication [5A2Y]	[68]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Insulin-aspart.	Acute diabete complication [5A2Y]	[68]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Glipizide.	Acute diabete complication [5A2Y]	[67]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Salicyclic acid and Budesonide.	Asthma [CA23]	[69]
Ofloxacin	DM0VQN3	Moderate	Additive CNS stimulant effects by the combination of Salicyclic acid and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[70]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Salicyclic acid and Kanamycin.	Bacterial infection [1A00-1C4Z]	[71]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Salicyclic acid and Streptomycin.	Bacterial infection [1A00-1C4Z]	[71]
Gemifloxacin	DMHT34O	Moderate	Additive CNS stimulant effects by the combination of Salicyclic acid and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[72]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS stimulant effects by the combination of Salicyclic acid and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[72]
ABT-492	DMJFD2I	Moderate	Additive CNS stimulant effects by the combination of Salicyclic acid and ABT-492.	Bacterial infection [1A00-1C4Z]	[70]
Rabeprazole	DMMZXIW	Minor	Decreased absorption of Salicyclic acid due to altered gastric pH caused by Rabeprazole.	Bacterial infection [1A00-1C4Z]	[73]
Levofloxacin	DMS60RB	Moderate	Additive CNS stimulant effects by the combination of Salicyclic acid and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[70]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of nephrotoxicity by the combination of Salicyclic acid and Etidronic acid.	Bone paget disease [FB85]	[74]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Salicyclic acid and Drospirenone.	Contraceptive management [QA21]	[75]
Ardeparin	DMYRX8B	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Ardeparin.	Coronary thrombosis [BA43]	[76]
Rivaroxaban	DMQMBZ1	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Rivaroxaban.	Deep vein thrombosis [BD71]	[76]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Vilazodone.	Depression [6A70-6A7Z]	[77]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Milnacipran.	Depression [6A70-6A7Z]	[77]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Escitalopram.	Depression [6A70-6A7Z]	[77]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Desvenlafaxine.	Depression [6A70-6A7Z]	[77]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Clomipramine.	Depression [6A70-6A7Z]	[77]
Dexlansoprazole	DM1DBV5	Minor	Decreased absorption of Salicyclic acid due to altered gastric pH caused by Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[73]
Brinzolamide	DMBAPFG	Major	Increased plasma concentration of Salicyclic acid and Brinzolamide due to competitive binding of plasma proteins.	Glaucoma [9C61]	[78]
Dichlorphenamide	DMH7IDQ	Major	Increased risk of metabolic acidosis by the combination of Salicyclic acid and Dichlorphenamide.	Glaucoma [9C61]	[78]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Salicyclic acid and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[79]
Sodium acetate anhydrous	DMH21E0	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Salicyclic acid caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[66]
Probenecid	DMMFWOJ	Moderate	Antagonize the effect of Salicyclic acid when combined with Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[80]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Salicyclic acid and Exjade.	Mineral absorption/transport disorder [5C64]	[81]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Salicyclic acid and Deflazacort.	Muscular dystrophy [8C70]	[69]
Prasugrel	DM7MT6E	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Prasugrel.	Myocardial infarction [BA41-BA43]	[82]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Sibutramine.	Obesity [5B80-5B81]	[77]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Epoprostenol.	Pulmonary hypertension [BB01]	[83]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Iloprost.	Pulmonary hypertension [BB01]	[83]
Gatifloxacin	DMSL679	Moderate	Additive CNS stimulant effects by the combination of Salicyclic acid and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[70]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Salicyclic acid and Dexamethasone.	Rheumatoid arthritis [FA20]	[69]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Salicyclic acid and Leflunomide.	Rheumatoid arthritis [FA20]	[79]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Salicyclic acid and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[69]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Salicyclic acid and Pitolisant.	Somnolence [MG42]	[80]
Apixaban	DM89JLN	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Apixaban.	Thrombosis [DB61-GB90]	[76]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Brilinta.	Thrombosis [DB61-GB90]	[80]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[67]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[68]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[68]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Salicyclic acid and Plazomicin.	Urinary tract infection [GC08]	[71]
Betrixaban	DM2C4RF	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Betrixaban.	Venous thromboembolism [BD72]	[76]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4306).
• [2] Drug information of Salicyclic acid, 2008. eduDrugs.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] BDDCS applied to over 900 drugs
• [5] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [6] FDA Approved Drug Products: HELIDAC Therapy (bismuth subsalicylate, metronidazole, and tetracycline)
• [7] Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
• [8] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [9] The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
• [10] Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10(1):193-9.
• [11] A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
• [12] Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy. Clin Transl Sci. 2018 Jul;11(4):352-364.
• [13] H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
• [14] Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450. Eur J Pharm Sci. 2015 Jun 20;73:49-56.
• [15] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [16] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [17] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [18] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [19] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [20] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [21] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [22] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [23] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [24] Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17.
• [25] Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos. 2007 Feb;35(2):201-8.
• [26] AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J. 2010 Jan 15;425(3):523-30.
• [27] Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008 Jun;10(2):311-21.
• [28] Interaction of atorvastatin with the human glial transporter SLC16A1. Eur J Pharmacol. 2016 Oct 5;788:248-254.
• [29] Cidofovir peptide conjugates as prodrugs. Journal of Organometallic Chemistry, 2005, 690(10):2673-2678.
• [30] Biotin. Biofactors. 2009 Jan-Feb;35(1):36-46.
• [31] Distribution of monocarboxylate transporters MCT1-MCT8 in rat tissues and human skeletal muscle. Appl Physiol Nutr Metab. 2006 Feb;31(1):31-9.
• [32] Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
• [33] Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999 Aug 1;341 ( Pt 3):529-35.
• [34] Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
• [35] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [36] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [37] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [38] An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669.
• [39] Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
• [40] Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
• [41] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [42] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
• [43] Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
• [44] Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
• [45] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [46] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [47] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [48] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [49] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [50] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [51] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [52] Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
• [53] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [54] Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
• [55] Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
• [56] Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
• [57] Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
• [58] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [59] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [60] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
• [61] Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
• [62] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [63] Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
• [64] Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
• [65] Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
• [66] Berg KJ "Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency." Eur J Clin Pharmacol 11 (1977): 111-6. [PMID: 837963]
• [67] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
• [68] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
• [69] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34. [PMID: 18956992]
• [70] Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
• [71] Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci 91 (1996): 187-91. [PMID: 8795442]
• [72] Product Information. Avelox (moxifloxacin) Bayer, West Haven, CT.
• [73] Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
• [74] Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
• [75] Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70. [PMID: 2865667]
• [76] Fausa O "Salicylate-induced hypoprothrombinemia: a report of four cases." Acta Med Scand 188 (1970): 403-8. [PMID: 5490567]
• [77] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
• [78] Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM "Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function." Br Med J (Clin Res Ed) 289 (1984): 347-8. [PMID: 6432091]
• [79] EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
• [80] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [81] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [82] Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
• [83] Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.